+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID05784428

Comparing Single and Multiple Fraction Stereotactic Ablative Radiotherapy for Treating Limited Metastatic Cancer SIMPLIFY-SABR-COMET Trial

Led by Robert Olson · Updated on 2026-09-24

598

Participants Needed

14

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are comparing two radiation therapy approachessingle fraction and multiple fraction stereotactic ablative radiotherapy SABRfor treating patients with 1 to 5 oligometastatic or oligo-progressive cancer lesions. This study aims to evaluate differences in treatment side effects, how long patients remain free from disease progression, quality of life, and cost-effectiveness. A subgroup will also examine the impact of healthcare provider-guided symptom management compared to questionnaire completion alone. Participants will be randomly assigned to receive either a single high-dose radiation treatment or multiple smaller doses spread over several sessions. Dosing varies by tumor location, including specific regimens for lung, bone, liver, spine, adrenal, lymph node, and brain lesions following institutional guidelines. In the subset of patients, quality of life questionnaires and symptom reporting will be used to guide healthcare interventions in one group while the other group completes questionnaires only. During the study, patients will complete quality of life assessments and symptom questionnaires at multiple time points up to five years post-treatment. Researchers will monitor adverse events, lesion control, progression-free survival, overall survival, and healthcare resource use. Radiation treatments follow a rigorous quality assurance process including CT simulation and organ contouring. The total study duration extends to approximately ten years, allowing long-term evaluation of outcomes and safety.

CONDITIONS

Brief Title

Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression

Research Team

R

Robert Olson, MD, MSC, FRCPC

H

Hadassah Abraham, MSc

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here